Abstract:Current therapeutic options for hearing loss rely on hearing aids, ossiculoplasty or cochlear implants. These devices have limitations, particularly in noisy acoustic environments. Therefore, interest in exploring aetiological treatments to improve not only auditory perception but also the quality of life of those affected is increasing. Gene therapy is a promising aetiological treatment that can fully restore auditory function. The success of gene therapy relies on the efficient delivery of therapeutic genes or genetic modifications to the cells of the inner ear that are designed to repair or replace defective genes and restore normal hearing function. Two main strategies for gene therapy involve the use of recombinant viral vectors and nonviral delivery vehicles. Owing to their excellent diffusion properties and compatibility with sensory cells, recombinant viral vectors, particularly adeno-associated viruses (AAVs), have dominated gene therapy in the cochlea. However, recombinant viral vectors have several drawbacks, such as limited transgene size, immunogenicity (particularly in neonates), and potential need for repeat administration. Nonviral vectors, such as cationic lipids and polymeric nanoparticles, are potential attractive alternatives. Nonviral vectors have several advantages, including low immunogenicity and unlimited transgene size. Recent studies have demonstrated significant auditory recovery in vivo using nonviral vectors in murine models. However, nonviral vectors are not as efficient as viral vectors in transferring genetic material. An alternative to nanoparticles is the use of other methods, such as electroporation. The main advantage of electroporation is that it can be used in combination with cochlear implantation and can target surface cells, but this method has a risk of cell damage. The goal of this review is to provide valuable insights into the current state of research on nonviral vectors for inner ear gene therapy and propose the exploration of innovative and effective gene therapy strategies for the treatment of hearing loss.

Application of Gene Therapy in Auditory System Diseases

Recent advances and future challenges in gene therapy for hearing loss

Advances in Gene Therapy Hold Promise for Treating Hereditary Hearing Loss

Gene therapy for deafness

Gene Therapy for Inherited Hearing Loss: Updates and Remaining Challenges

AAV‐mediated Gene Therapy for Hereditary Deafness: Progress and Perspectives

Gene therapy: an emerging therapy for hair cells regeneration in the cochlea

Milestones toward cochlear gene therapy for patients with hereditary hearing loss

Gene therapy for hearing loss: Current status and future prospects of non-viral vector delivery systems

Gene Therapy for Human Sensorineural Hearing Loss

In Utero Gene Therapy and its Application in Genetic Hearing Loss

Current Advances in Gene Therapies of Genetic Auditory Neuropathy Spectrum Disorder

Gene therapy for deafness: are we there now?

Genetic Hearing Loss and Gene Therapy

Polymer‐Based Nanoparticles for Inner Ear Targeted Trans Differentiation Gene Therapy.

Stem Cells and Gene Therapy in Progressive Hearing Loss: the State of the Art

The applications of CRISPR/Cas-mediated genome editing in genetic hearing loss

Exploring delivery systems for targeted nanotechnology-based gene therapy in the inner ear

Deafness: from genetic architecture to gene therapy

Advancements and future prospects of adeno-associated virus-mediated gene therapy for sensorineural hearing loss

Potential of Gene and Cell Therapy for Inner Ear Hair Cells